Business opportunities

Areas of Excellence

  • Cellular and Tissue Production
  • Biology of Blood Components
  • Technology Transfer Technology

Platforms and Partnership Opportunities

Over the years, the R&D Division has developed and broadened a unique technological expertise. Areas of excellence and technology platforms implemented by Héma-Québec include:

  • Culture of various cell populations (hematopoietic cells, B lymphocytes, mesenchymal stem cells)
  • Analysis of cellular populations by multi-parametric flow cytometry and florescence microscopy, including confocal microscopy
  • In vitro and in vivo models of immune response and stem cell transplantation
  • Serology and genotyping of red cells and platelets
  • Nanotechnology applications (direct genotyping without gene amplification)
  • Development of quality evaluation processes for blood components

Héma-Québec believes that mobilizing the driving forces behind R&D in Québec contributes to the improvement of human health. Towards this goal, we encourage partnerships with academic and industrial stakeholders. These networking opportunities are aimed at fostering the growth of a dynamic and widespread ecosystem in the life sciences.

Héma-Québec offers its expertise and technological resources through various partnership models, such as:

  • esearch collaboration agreements
  • biological material transfer agreements
  • service agreements
  • research contracts

Our Patent Portfolio

Héma-Québec acknowledges that intellectual property developed by its staff constitutes a valuable asset to its mission and considers as its responsibility that this intellectual property be exploited in an optimal fashion for the benefit of all Quebecers.

Héma-Québec seeks to develop its patented technologies and other intellectual properties, preferably through licensing agreements. The patented technologies available for licensing are:

Description

This invention improves the in vitro expansion of hematopoietic stem cells, as well as the in vitro differentiation of these cells into blood platelet-producing cells. This technology is of clinical relevance, specially in the design of therapies involving hematopoietic stem cell transplantation

Countries/Territories

United States of America
Canada
Europe (granted European patent validated in France, Germany, and United Kingdom)

To learn more

Description

This invention claims a method allowing long-term in vitro expansion of memory B lymphocytes, as well as the production of polyclonal immunoglobulins. This technology could be a valuable asset in the development of novel methods of in vitro antibody production.

Countries/Territories

Canada
United States
Europe (pending)

To learn more 

Description

This invention concerns a system of pouches filled with a eutectic gel and their use in the packaging of whole blood, allowing to rapidly cool and hold fresh blood at 20-24°C during transport to a blood processing center. Rapid cooling and temperature hold of whole blood at 20-24°C allows for a more standardized and enhanced quality of blood components.

Countries/Territories

United States (granted patents on methods for cooling whole blood, and for fabricating eutectic gel-containing pouches; patent pending: continuation of patent on method for fabricating eutectic gel-containing pouches)
Canada (pending)
Europe (pending)

To learn more

Description

This invention focuses on core-shell nanoparticles made up of a silver core within a silica shell, to which fluorescent markers and ligands that are specific to cellular targets are covalently attached. The synthesis method is very simple, and allows a high yield at low cost. These nanoparticles have various applications in optical and fluorescence microscopy, flow cytometry, and red blood cell phenotyping.

Countries/Territories

United States (provisional patent application)

To learn more

Description

This invention focuses on the detection of extracellular mitochondria and its use as a marker of inflammation and quality control assay for platelet concentrates. The prevention of the degradation of extracellular mitochondria in biological products, as well as the treatment of patients suffering from inflammatory pathologies, are also claimed.

Countries/Territories

United States (provisional patent application)

To learn more

Are you interested in one of our technologies?

Héma-Québec seeks to develop its patented technologies and other intellectual properties, preferentially through licensing agreements.

Collaborations and partnerships

Héma-Québec is also willing to reach collaboration and partnership agreements with third parties interested in our technologies and our expertise. Examples of such agreements include:

  • research collaboration agreements;
  • biological material transfer agreements;
  • service agreements;
  • research contract agreements.

For more information, please contact:

Yves Blais, Ph.D., M.B.A.
Vice-president, Research and Development
Héma-Québec 1070, avenue des Sciences-de-la-Vie
Québec (Québec) G1V 5C3
Telephone: 418-780-4362, ext. 3248, or toll-free 1-800-267-9711, ext. 3248
Fax: 418-780-2091